Form 4: VYNE Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Lori Payton, Chief Development Officer of VYNE Therapeutics Inc., received 99,827 shares of common stock on October 29, 2026.
Summary
- Grant/award: acquired 99,827 Stock Option (Right to Buy) on October 29, 2026; holds 99,827 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Lori Payton — Officer (Chief Development Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-29 | Grant/award | Stock Option (Right to Buy) | 99,827 | — | — | 99,827 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-29 | Grant/award (99,827 shares) |
Keywords
insider transaction, Form 4, YARW, Yarrow Bioscience, Inc., neutral, Lori Payton
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.